With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
亘喜生物卖身阿斯利康 为manbetx3.0 药企指引新出路？

The Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant.
亘喜生物专注细胞疗法赛道，其进展最快的核心产品仍处于临床一期阶段，未来将在中、美展开多项临床试验，此举有望规避现金流不足风险。